Screening And Future Enhanced MRI

Información del proyecto

SAFE-MRI

Identificador del acuerdo de subvención: 101087701

DOI

10.3030/101087701

Fecha de la firma de la CE 24 Abril 2023

Fecha de inicio 1 Junio 2023

Fecha de finalización 31 Mayo 2028

Financiado con arreglo a

• European Research Council (ERC)

Coste total

€ 2 984 796,00

Aportación de la UE

€ 2 984 796,00

Coordinado por

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Netherlands

Periodic Reporting for period 1 - SAFE-MRI (Screening And Future Enhanced MRI)

Período documentado: 2023-06-01 hasta 2025-11-30

Resumen del contexto y de los objetivos generales del proyecto

SAFE-MRI aims to prevent needless mortality from breast cancer by optimizing the use and performance of dedicated breast MRI. SAFE-MRI focusses particularly on the value of this technique for screening in younger women. SAFE-MRI further aims at improving breast MRI by reducing the need for contrast administration. This is a major downside of breast MRI - for women (iv-canulation and a small risk of allergic reactions) and the environment (pollution of surface water). We aim to enhance signal changes using a strongly reduced dose of contrast with advanced deep learning (DL). Further studies are tailored at assessment of unenhanced MRI. Particularly, we are validating novel diffusion weighted imaging (DWI) sequences capable of generating high resolution diagnostic images within short scan times using DL-based reconstruction. Furthermore, we investigate arterial spin labelling (ASL) based breast imaging strategies that show perfusion without the need for contrast administration. Finally, we will combine unenhanced MRI techniques in a general adversarial network to construct synthetic breast MRI images. Repeated reader studies are being designed to assess image quality and diagnostic value.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

SAFE-MRI is an hybrid project that consists of advanced MRI development for low- and no contrast breast MRI development, along with a prospective screening study in women aged 45. In this progress report we address the advances in the MRI development phase as these have yet led to tangible results. Particular successes have been achieved in the evaluation of new DL based DWI sequences and in the generation of synthetic MRI as described in more detail in the narrative progress report.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

The key area where we are currently focussing is in the optimisation of synthetic MRI, as this has the potential to revolutionise the way we use MRI for screening by obviating the need for intravenous contrast administration. This may also have significant environmental benefits, as it would reduce the excretion of contrast media in waste water. (recently gadolinium was even shown to be present in beer...).